Literature DB >> 2545641

Effects of betaxolol/timolol on epinephrine stimulated cyclic-AMP levels in human trabecular meshwork cells.

J Polansky1, Z Friedman, D Fauss, R Kurtz, J Alvarado.   

Abstract

The effects of timolol and betaxolol were compared for blocking beta agonist stimulation of cyclic-AMP in cultured human trabecular meshwork cells. Epinephrine (10(-5) M) produced a large and rapid increase in HTM cyclic-AMP; timolol (10(-6) M), at concentrations readily achieved in the aqueous humor after 0.5% eyedrops, completely blocked this effect. Recovery from timolol treatment appeared to be relatively slow, with only a 30-40% recovery observed by 9 hours. In comparison, betaxolol (10(-6) M) produced a smaller blockade of the epinephrine effects; a rapid recovery from the betaxolol effects was observed, with a greater than half-maximal response to epinephrine observed 15 minutes after removal of this beta blocker. These findings may help to explain the clinical observations of an outflow facility effect of epinephrine when used in combination protocols with betaxolol, but not with timolol.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2545641     DOI: 10.1007/BF02028646

Source DB:  PubMed          Journal:  Int Ophthalmol        ISSN: 0165-5701            Impact factor:   2.031


  10 in total

1.  Influences of cyclic nucleotides on outflow facility in the vervet monkey.

Authors:  A H Neufeld
Journal:  Exp Eye Res       Date:  1978-10       Impact factor: 3.467

2.  Adenosine 3',5'-monophosphate increases the outflow of aqueous humor from the rabbit eye.

Authors:  A H Neufeld; D K Dueker; T Vegge; M L Sears
Journal:  Invest Ophthalmol       Date:  1975-01

3.  Characterization of beta-adrenergic receptors in cultured human trabecular cells and in human trabecular meshwork.

Authors:  M B Wax; P B Molinoff; J Alvarado; J Polansky
Journal:  Invest Ophthalmol Vis Sci       Date:  1989-01       Impact factor: 4.799

4.  Isolation and evaluation of target cells in glaucoma research: hormone receptors and drug responses.

Authors:  J R Polansky; J A Alvarado
Journal:  Curr Eye Res       Date:  1985-03       Impact factor: 2.424

5.  Studies on human trabecular cells propagated in vitro.

Authors:  J R Polansky; R Weinreb; J A Alvarado
Journal:  Vision Res       Date:  1981       Impact factor: 1.886

6.  Effects of norepinephrine, isoproterenol and sympathetic stimulation on aqueous humour dynamics in vervet monkeys.

Authors:  A Bill
Journal:  Exp Eye Res       Date:  1970-07       Impact factor: 3.467

7.  Human trabecular cells. II. Growth pattern and ultrastructural characteristics.

Authors:  J A Alvarado; I Wood; J R Polansky
Journal:  Invest Ophthalmol Vis Sci       Date:  1982-10       Impact factor: 4.799

8.  Trabecular meshwork cell culture in glaucoma research: evaluation of biological activity and structural properties of human trabecular cells in vitro.

Authors:  J R Polansky; I S Wood; M T Maglio; J A Alvarado
Journal:  Ophthalmology       Date:  1984-06       Impact factor: 12.079

9.  Human trabecular cells. I. Establishment in tissue culture and growth characteristics.

Authors:  J R Polansky; R N Weinreb; J D Baxter; J Alvarado
Journal:  Invest Ophthalmol Vis Sci       Date:  1979-10       Impact factor: 4.799

10.  Additive effect of betaxolol and epinephrine in primary open angle glaucoma.

Authors:  R C Allen; D L Epstein
Journal:  Arch Ophthalmol       Date:  1986-08
  10 in total
  2 in total

1.  Epinephrine effects on major cell types of the aqueous outflow pathway: in vitro studies/clinical implications.

Authors:  J A Alvarado; L Franse-Carman; G McHolm; C Murphy
Journal:  Trans Am Ophthalmol Soc       Date:  1990

2.  Treatment of glaucoma by prostaglandin agonists and beta-blockers in combination directly reduces pro-fibrotic gene expression in trabecular meshwork.

Authors:  Sushma Tejwani; Praveen Machiraju; Archana Padmanabhan Nair; Anuprita Ghosh; Raunak Kumar Das; Arkasubhra Ghosh; Swaminathan Sethu
Journal:  J Cell Mol Med       Date:  2020-04-08       Impact factor: 5.310

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.